StockIQpro
NASDAQ:ELTX

Elicio Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Elicio Therapeutics, Inc. reported net income of −$39.6M in fiscal 2025. Free cash flow was −$37.0M, and the diluted share count rose 25.5%.Summary generated from Elicio Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equity6.11
Free cash flow−$37.0M
FCF marginn/a
Share count change+25.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue282n/an/an/a
Operating income−39−24−36−45−38
Net income−55−28−35−52−40
Free cash flow−53−23−33−37−37

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations